Amgen Gets $70M In Biosimilar Patent Suit Against Hospira
A Delaware federal jury awarded Amgen Inc. $70 million in damages late Friday after finding that Hospira Inc. infringed a patent for the anemia treatment Epogen, rejecting Hospira's argument that it...To view the full article, register now.
Already a subscriber? Click here to view full article